Vincerx Pharma, Inc.
CIK 0001796129
Revenue (TTM)
—
Q1 Apr 2025
Net Income (TTM)
−$27.08M
+25.1% YoY
Q1 Apr 2025
EPS Diluted (TTM)
−$13.08
0.0% YoY
Q1 Apr 2025
Gross Margin
—
Q1 Apr 2025
Operating Margin
—
Q1 Apr 2025
Net Margin
—
Q1 Apr 2025
Free Cash Flow (TTM)
−$40.31M
Q1 Apr 2025
Cash
$4.44M
Q1 Apr 2025
Total Debt
—
Q1 Apr 2025
Shares Outstanding
5.23M sh
Q1 Apr 2025
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.